Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Phase 3positivedenecimigPositive

AI Analysis

Summary

Novo Nordisk's investigational denecimig (Mim8) demonstrated positive long-term safety and efficacy results in the Phase 3 FRONTIER4 extension study for hemophilia A across multiple dosing frequencies in participants of all ages and disease severities.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Positive results in long-term safety and efficacy demonstrated in FRONTIER4 extension study across once-weekly, once-every-two-weeks, and once-monthly dosing regimens in hemophilia A participants of all ages and disease severities

Importance:7/10

Sentiment:

0.80

hemophilia Along-term safetyefficacyFRONTIER4ISTH 2026subcutaneous

Related Companies

$NVO

Read the original article

Published by PR Newswire Pharma on July 11, 2026 12:05 PM

Read Original